JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.
Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.
A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.
The American College of Rheumatology (ACR) has issued a guidance document for rheumatologists and rheumatology health professionals to consider as practices, business and patient care begins to reopen in this next phase of the COVID-19 pandemic.
Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.
In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population.
According to a small, observational study out of UCLA published as correspondence in the NEJM on July 21, 2020, those with mild COVID-19 symptoms showed an approximate antibody half-life of 73 days.
The number of reporting cases of COVID-19 infection tends to underestimate the true prevalence of infection as only the more severe cases (e.g.,acute respiratory syndrome) get tested or go to the hospital.
A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS) with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving supporti
Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury. The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day mortalit
From January 1, 2020–May 18, 2020, approximately 1.3 million cases of coronavirus disease 2019 (COVID-19) and 83,000 COVID-19–associated deaths were reported in the United States.
Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow.
NEJM NEJM( View Tweet)
Mohammad A. Ursani MD, RhMSUS DrMAUrsani( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Jeff Sparks jeffsparks( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Victoria Shanmugam VickiShanmugam( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
